Aurinia Pharmaceuticals Inc (AUPH)vsEli Lilly and Company (LLY)
AUPH
Aurinia Pharmaceuticals Inc
$15.72
+3.22%
HEALTHCARE · Cap: $2.02B
LLY
Eli Lilly and Company
$966.99
+1.95%
HEALTHCARE · Cap: $869.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 24121% more annual revenue ($72.25B vs $298.30M). AUPH leads profitability with a 100.0% profit margin vs 35.0%. AUPH trades at a lower P/E of 7.3x. LLY earns a higher WallStSmart Score of 78/100 (B+).
AUPH
Strong Buy69
out of 100
Grade: B-
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 65 in profit
Keeps 100 of every $100 in revenue as profit
Strong operational efficiency at 53.3%
Earnings expanding 56.3% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Distress zone — elevated risk
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 100.0% and operating margin at 53.3%. Revenue growth of 24.4% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : AUPH
The primary concerns for AUPH are Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
AUPH carries more volatility with a beta of 1.45 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 69/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?